MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3760/cma.j.issn.0253-2727.2015.07.005

Медицинская библиотека · Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015

[The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].

Bao Xiebing, Qiu Huiying, Chen Suning, Ma Xiao, Tang Xiaowen, Fu Chengcheng, Sun Aining, Wu Depei

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To understand the prognostic value of early monitoring BCR-ABL transcripts in patients with chronic myeloid leukemia (CML) after treatment with imatinib, and to provide the information for early assessment of prognosis and treatment options.

METHODS

The clinical data of 251 patients with CML in chronic phase (CML-CP) who received imatinib as first-line therapy were retrospectively analyzed, the progression-free survival (PFS)and overall survival (OS) between different BCR-ABL transcriptional level at 3 and 6 month after imatinib treatment were compared. Meanwhile, Chi-square test and logistic regression were used to analyze the risk factors for disease progression.

RESULTS

At 3 months after imatinib treatment BCR-ABL transcriptional levels>10%, >1%-≤ 10% and ≤ 1% were found in 92, 94 and 64 patients, their PFS were 53.3%, 71.3% and 86.2%, respectively. The results showed that the PFS of patients with low BCR-ABL transcriptional levels was significantly superior to that with high BCR-ABL transcriptional levels for CML at 3 months treatment (P<0.05). The OS of three group did not reach statistical significance (92.4% vs 96.8% vs 93.8%, P> 0.05). When 182 patients received imatinib treatment at 6 months, 22 patients with BCR-ABL transcriptional levels>10%, 50>1% -≤ 10% and 110 ≤ 1%, their PFS were 27.3% vs 66.0% vs 82.7% (P<0.05), the OS of three groups were 86.4% vs 94.0% vs 100%. There were significant differences among the three groups (P<0.05). Logistic regression confirmed that the level of BCR-ABL transcriptional level at 3 and 6 months after imatinib treatment was independent factor to influence the progress of disease.

CONCLUSION

It is important for the prognosis evaluation of CML patients to monitor BCR-ABL transcriptional level at 3 and 6 months after imatinib treatment.

Для цитирования: Bao Xiebing, Qiu Huiying, Chen Suning, Ma Xiao, Tang Xiaowen, Fu Chengcheng, Sun Aining, Wu Depei. [The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2015. DOI: 10.3760/cma.j.issn.0253-2727.2015.07.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.